Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 182

1.

Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.

Généreux P, Rutledge DR, Palmerini T, Caixeta A, Kedhi E, Hermiller JB, Wang J, Krucoff MW, Jones-McMeans J, Sudhir K, Simonton CA, Serruys PW, Stone GW.

Circ Cardiovasc Interv. 2015 May;8(5). pii: e001362. doi: 10.1161/CIRCINTERVENTIONS.114.001362.

PMID:
25940520
2.

Relationship Between Oral Health Literacy and Oral Health Status Among College Students.

Kanupuru KK, Fareed N, Sudhir KM.

Oral Health Prev Dent. 2015 Jan 20. doi: 10.3290/j.ohpd.a33444. [Epub ahead of print]

PMID:
25610917
3.

Three-year data from the XIENCE V INDIA study: safety and efficacy of XIENCE V in 1000 real world Indian patients.

Seth A, Patel TM, Stuteville M, Kumar R, Mullasari AS, Kaul U, Mathew R, Sreenivas Kumar A, Ying SW, Sudhir K.

Indian Heart J. 2014 May-Jun;66(3):302-8. doi: 10.1016/j.ihj.2014.03.007. Epub 2014 Apr 18.

4.

The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled.

Abizaid A, Ribamar Costa J Jr, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong WF, Sudhir K, Serruys PW; ABSORB EXTEND investigators.

EuroIntervention. 2015 Apr;10(12):1396-401. doi: 10.4244/EIJV10I12A243.

5.

Relationship between stimulated salivary factors, dental caries status and nutritional condition among institutionalized elderly people.

Srinivasulu G, Fareed N, Sudhir KM, Krishna Kumar RV.

Oral Health Dent Manag. 2014 Mar;13(1):49-53.

PMID:
24603916
6.

5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.

JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.

7.

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.

JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.

8.

Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy.

Sudhir K, Hermiller JB, Ferguson JM, Simonton CA.

ISRN Cardiol. 2013 Jun 23;2013:748736. doi: 10.1155/2013/748736. Print 2013.

9.

Evaluation of XIENCE V everolimus-eluting and Taxus Express2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 years.

Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW.

Am J Cardiol. 2013 Jun 1;111(11):1580-6. doi: 10.1016/j.amjcard.2013.01.330. Epub 2013 Mar 15.

PMID:
23499270
10.

Incidence, time course and predictors of early vs. late target lesion revascularisation after everolimus-eluting stent implantation: a SPIRIT V substudy.

Niccoli G, Stuteville M, Sudhir K, Li D, Montone RA, Bolognese L, Grube E.

EuroIntervention. 2013 Jul;9(3):353-9. doi: 10.4244/EIJV9I3A57.

11.

Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study.

Džavík V, Kaul U, Guagliumi G, Chevalier B, Smits PC, Stuteville M, Li D, Sudhir K, Grube E.

Catheter Cardiovasc Interv. 2013 Sep 1;82(3):E163-72. doi: 10.1002/ccd.24775. Epub 2013 May 3.

PMID:
23225766
12.

Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.

Sudhir K, Hermiller JB, Naidu SS, Henry TD, Mao VW, Zhao W, Ferguson JM, Wang J, Jonnavithula L, Simonton CA, Rutledge DR, Krucoff MW; XIENCE V USA Investigators.

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E385-94. doi: 10.1002/ccd.24749. Epub 2013 Mar 28.

PMID:
23172848
14.

Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial.

Yamasaki M, Tsujino I, Lima-Filho MO, Ako J, Shimohama T, Hasegawa T, Sakurai R, Sudhir K, Stone GW, Waseda K, Honda Y, Fitzgerald PJ.

EuroIntervention. 2012 Oct;8(6):724-31. doi: 10.4244/EIJV8I6A112.

15.

Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study.

Hermiller JB, Rutledge DR, Gruberg L, Katopodis JN, Lombardi W, Mao VW, Zhao W, Sharma SK, Tamboli HP, Wang J, Jonnavithula L, Sudhir K, Krucoff MW.

J Interv Cardiol. 2012 Dec;25(6):565-75. doi: 10.1111/j.1540-8183.2012.00766.x. Epub 2012 Sep 23.

PMID:
22998355
16.

Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.

Kedhi E, Stone GW, Kereiakes DJ, Serruys PW, Parise H, Fahy M, Simonton CA, Sudhir K, Sood P, Smits PC.

EuroIntervention. 2012 Sep;8(5):599-606. doi: 10.4244/EIJV8I5A92.

17.

Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing.

Saito S, Nakamura S, Fujii K, Nakamura M, Isshiki T, Hirayama H, Kikuchi T, Fujita H, Nonogi H, Mitsudo K, Kimura T, Igarashi K, Saito K, Lansky AJ, Stone GW, Honda Y, Waseda K, Fitzgerald PJ, Sudhir K.

J Invasive Cardiol. 2012 Sep;24(9):444-50.

18.

Functional tumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells.

Adurthi S, Mukherjee G, Krishnamurthy H, Sudhir K, Bafna UD, Umadevi K, Jayshree RS.

Int J Gynecol Cancer. 2012 Sep;22(7):1130-7. doi: 10.1097/IGC.0b013e318262aa53.

PMID:
22872166
19.

SPIRIT Women, evaluation of the safety and efficacy of the XIENCE V everolimus-eluting stent system in female patients: referral time for coronary intervention and 2-year clinical outcomes.

Morice MC, Mikhail GW, Mauri i Ferré F, Modena MG, Strasser RH, Grinfeld L, Sudhir K, Stuteville M, Papeleu P, Li D, Rutledge D, Windecker S.

EuroIntervention. 2012 Jul 20;8(3):325-35. doi: 10.4244/EIJV8I3A51.

20.

Distribution patterns of enamel fluorosis in permanent dentition.

Sudhir KM, Suresh S, Prashant GM, Reddy VV, Shafiulla M, Chandu GN.

Oral Health Prev Dent. 2012;10(2):167-74.

PMID:
22763597
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk